BlackRock Health Sciences Trust (BME) Stock Score, Valuation & Financial Research
BlackRock Health Sciences Trust is in the Financial Services sector and Asset Management industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 62/100.
Quick answer for BME
BlackRock Health Sciences Trust currently has a Wall Street Score of 62/100. The stored market price is $44.34. Its financial score is 32/100. Its valuation score is 100/100. The latest WSS change is -0.5 points. These figures are a research snapshot, not a buy or sell recommendation.
What BlackRock Health Sciences Trust does
BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.
BME financial snapshot
- Wall Street Score:
- 62/100
- Current price:
- $44.34
- Market capitalization:
- $573.1M
- Revenue:
- $94.2M
- Net income:
- $78.0M
- Free cash flow:
- $-4.4M
- Cash:
- $361
- Total debt:
- $688K
- EPS:
- 6.07
- P/E ratio:
- 7.3x
- Financial score:
- 32/100
- Valuation score:
- 100/100
- Revenue score:
- 56/100
What stands out
- Reported year-over-year revenue growth is +1.6%.
- Free cash flow is $-4.4M, showing cash burn in the current stored period.
- The balance sheet shows $361 of cash versus $688K of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.5 points: BME decreased 0.5 points because Valuation declined by 2.5 points.
- The current research record carries a listed fund vehicle warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BME
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.